decemb
case
lifethreaten
pneumonia
report
wuhan
china
novel
coronaviru
identifi
sourc
infect
number
report
case
rapidli
increas
wuhan
well
chines
citi
viru
also
identifi
part
world
januari
world
health
organ
declar
diseas
public
health
emerg
intern
concern
februari
chines
govern
report
confirm
case
mainland
china
report
confirm
case
countri
outsid
china
viru
contain
within
wuhan
major
citi
china
like
experi
local
outbreak
foreign
citi
close
transport
link
china
could
also
becom
outbreak
epicent
without
care
public
health
intervent
japan
econom
impact
social
disrupt
report
sever
japanes
individu
japanesegovernmentchart
airplan
wuhan
japan
report
coronavirusposit
also
humantohuman
transmiss
confirm
nara
prefectur
januari
sinc
public
shown
anxietyrel
behavior
signific
shortag
mask
antisept
drug
store
econom
impact
substanti
stock
price
drop
china
japan
part
world
also
show
synchron
declin
februari
one
die
directli
coronaviru
infect
japan
tragic
howev
govern
worker
charg
isol
returne
die
appar
suicid
first
time
japanes
peopl
experienc
imperceptibleag
emergenciesoften
dub
cbrne
ie
chemic
biolog
radiolog
nuclear
highyield
explos
japan
endur
two
atom
bomb
sarin
ga
attack
influenza
pandem
fukushima
nuclear
accid
carri
fear
risk
associ
unseen
agent
event
provok
social
disrupt
overwhelm
sensat
news
headlin
imag
ad
anxieti
fear
situat
foster
rumor
hype
inform
individu
fill
absenc
inform
rumor
affect
peopl
subject
societ
reject
discrimin
stigmat
fukushima
survivor
tend
attribut
physic
chang
event
regardless
actual
exposur
decreas
perceiv
health
associ
decreas
life
expect
fear
unknown
rais
anxieti
level
healthi
individu
well
preexist
mental
health
condit
exampl
studi
anthrax
letter
attack
usa
show
longterm
mental
health
advers
well
lower
health
percept
infect
employe
respond
public
fear
manifest
discrimin
stigmat
scapego
specif
popul
author
scientist
write
letter
coronaviru
emerg
rapidli
evolv
nonetheless
less
predict
expect
mentalphys
health
consequ
vulner
popul
first
peopl
emot
respons
like
includ
extrem
fear
uncertainti
moreov
neg
societ
behavior
often
driven
fear
distort
percept
risk
experi
might
evolv
includ
broad
rang
public
mental
health
concern
includ
distress
reaction
insomnia
anger
extrem
fear
ill
even
expos
health
risk
behavior
increas
use
alcohol
tobacco
social
isol
mental
health
disord
posttraumat
stress
disord
anxieti
disord
depress
somat
lower
perceiv
health
essenti
mental
health
profession
provid
necessari
support
expos
deliv
care
second
particular
effort
must
direct
vulner
popul
includ
infect
ill
patient
famili
colleagu
ii
chines
individu
commun
iii
individu
preexist
mentalphys
condit
last
least
iv
healthcar
aid
worker
especi
nurs
physician
work
directli
ill
quarantin
person
noth
els
death
govern
quarantin
worker
must
remind
us
recogn
extent
psycholog
stress
associ
impercept
agent
emerg
give
paramount
weight
integr
right
vulner
popul
slower
titrat
lamotrigin
reduc
risk
rash
lamotrigin
ltg
wide
use
epilepsi
bipolar
disord
howev
risk
ltginduc
skin
rash
titrat
speed
differ
depend
combin
drug
enhanc
inhibit
ltg
metabol
enzym
risk
factor
note
clinic
practic
greatest
risk
factor
precis
elucid
therefor
retrospect
review
clinic
record
assess
risk
ltginduc
skin
rash
decemb
septemb
patient
taken
ltg
recruit
dokkyo
medic
univers
hospit
patient
diagnos
accord
dsmivtr
criteria
bipolar
relat
disord
depress
disord
epilepsi
schedul
follow
recommend
concern
standard
titrat
studi
slow
group
defin
slower
titrat
recommend
evalu
period
within
week
rash
often
occur
within
time
period
lowinitialdos
group
defin
lower
first
dose
standard
regard
factor
evalu
combin
drug
equival
antipsychot
antidepress
benzodiazepin
antiparkinson
drug
valproat
carbamazepin
lithium
age
sex
diagnosi
retrospect
crosssect
studi
patient
medic
record
collect
data
clinic
record
approv
obtain
institut
review
board
dokkyo
medic
univers
school
medicin
approv
method
written
inform
consent
provid
particip
obtain
consent
optout
system
anonym
clinic
record
use
studi
inform
could
identifi
individu
prepar
particip
spontan
consent
hospit
treatment
none
compromis
capac
consent
whether
patient
ltginduc
rash
judg
base
doctor
descript
medic
record
accord
medic
record
particip
categor
rashposit
patient
doctor
decid
ceas
ltg
treatment
rash
logist
regress
analysi
appli
examin
risk
factor
rash
factor
includ
logist
regress
model
pvalu
report
twotail
statist
signific
consid
pvalu
less
total
patient
initi
dose
higher
standard
patient
initi
dose
lower
standard
regard
titrat
patient
rapid
titrat
patient
slower
titrat
patient
prescrib
ltg
rash
occur
patient
one
patient
diagnos
stevensjohnson
syndrom
howev
rash
patient
sever
natur
patient
slow
titrat
rash
occur
contrari
rash
occur
patient
receiv
standard
titrat
analyz
relationship
rash
occurr
age
sex
diagnosi
titrat
speed
initi
dose
ltg
benzodiazepin
dose
diazepam
equival
antidepress
dose
imipramin
equival
antipsychot
dose
chlorpromazin
equival
antiparkinson
drug
dose
biperiden
equival
lithium
dose
valproic
acid
dose
carbamazepin
dose
logist
regress
analysi
indic
slow
ltg
titrat
factor
significantli
relat
low
rash
occurr
tabl
sequenti
analysi
subject
whose
initi
ltg
dose
higher
whose
ltg
titrat
speed
faster
exclud
thirti
patient
rapid
titrat
higher
initi
dose
one
patient
analysi
also
reveal
slower
ltg
titrat
prefer
prevent
rash
occurr
tabl
methodolog
sever
limit
first
might
fals
posit
ltginduc
rash
fact
rate
benign
ltginduc
rash
rate
sever
rash
rare
howev
situat
might
happen
clinic
practic
patient
sometim
decid
selfdiscontinu
medic
next
visit
without
doctor
judgment
judgment
may
fals
could
safer
difficult
distinguish
sever
rash
benign
rash
second
patient
rapid
titrat
rash
occur
three
patient
howev
could
conclud
rapid
titrat
safe
ltg
sampl
size
small
furthermor
addit
studi
requir
clarifi
risk
factor
final
patient
data
includ
detail
regard
liver
kidney
function
henc
result
might
influenc
factor
fact
consid
studi
investig
risk
factor
skin
rash
due
ltg
administr
real
clinic
set
slower
titrat
standard
recommend
indic
significantli
lower
risk
rash
induc
ltg
therefor
recommend
ltg
titrat
slower
reduc
rash
incid
kazutaka
shimoda
receiv
research
support
novarti
pharma
kk
dainippon
sumitomo
pharma
co
astella
pharma
inc
meiji
seika
